Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

KOL Strategy

- PMLiVE

Resisting the resistance

How genomics can help us win the fight against AMR

- PMLiVE

Protecting the Heart Through Education at ESC 2023

Medscape Education Global is joining cardiology professionals from across Europe for ESC 2023 in Amsterdam. This year’s congress theme is “Joining Forces to Protect the Heart,” and Medscape will be...

Medscape Education

- PMLiVE

UK government allocates £250m for more NHS hospital beds in England

The funds will provide another 5,000 beds this winter to relieve pressure on hospitals and cut waiting times

- PMLiVE

NHS achieves new record for cancer checks for patients

Nearly three million patients have had cancer checks by the NHS in the last year

- PMLiVE

Medscape’s Rare Disease Learning Center Has Reached 1 Million Learners

The Pathways in Rare Disease Learning Center celebrates a momentous achievement - engaging one million learners in its educational initiatives. This milestone signifies a profound impact on clinician confidence in...

Medscape Education

- PMLiVE

Achieving communications excellence with the healthcare workforce of the future

By Roy Rogers

- PMLiVE

Signal to noise: tuning social media to frequency HCP

By Aaron Hall

- PMLiVE

NHS to initiate flu vaccine roll-outs for children from September

The roll-outs are part of the NHS winter flu and COVID-19 vaccination programme

- PMLiVE

NICE recommends AI technologies for radiotherapy treatment planning

AI technology could provide the NHS with significant time and cost benefits

- PMLiVE

NHS England to offer millions of children flu vaccines from September

The rollout is part of the NHS winter flu and COVID-19 vaccination programme

- PMLiVE

US survey reveals ‘critical’ drug shortages are affecting cancer care

Approximately 99% of US pharmacists reported that they are experiencing drug shortages

- PMLiVE

Janssen’s Talvey granted FDA accelerated approval for difficult-to-treat blood cancer

The therapy showed an overall response rate of more than 70% in a broad range of patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links